In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer

Journal of Controlled Release

Volumn 165, Issue 3, 2013, Pages 199-206

  Asmus, Lutz R ^a   Tille, Jean Christophe ^b   Kaufmann, Béatrice ^a   Melander, Louise ^c   Weiss, Torsten ^c   Vessman, Kerstin ^c   Koechling, Wolfgang ^c   Schwach, Grégoire ^c   Gurny, Robert ^a   Möller, Michael ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Biocompatibility; In vivo release; Keywords; Peptide stability; Sustained release implants; Triptorelin

Indexed keywords

A-STABILITY; ACTIVE COMPOUNDS; AQUEOUS ENVIRONMENT; CLINICAL USE; DEGRADABLE POLYMERS; DRUG RELEASE; EFFECTIVE CONCENTRATION; ELEVATED TEMPERATURE; EXTRACELLULAR MATRICES; IN-SITU FORMING; IN-VIVO; KEYWORDS; PLASMA LEVELS; POLY LACTIC ACID; POLY(LACTIC-CO-GLYCOLIC ACID); POLYMERIC MATRICES; PRESENCE OF WATER; PROTECTION EFFECT; STORAGE CONDITION; STRUCTURE-RELATED; SUSTAINED-RELEASE; TRIPTORELIN; VISCOUS POLYMERS; VITRO-IN VIVO CORRELATION; ZERO ORDER;

BIOCOMPATIBILITY; BUFFER STORAGE; COPOLYMERS; LACTIC ACID; PEPTIDES; RATS; STABILITY;

POLYMERS;

GONADORELIN RECEPTOR; POLYGLACTIN; POLYMER; TRIPTORELIN;

ARTICLE; BIOCOMPATIBILITY; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TEMPERATURE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; POLYMERS; RATS; RATS, SPRAGUE-DAWLEY; TRIPTORELIN PAMOATE;

EID: 84871548529     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.11.014     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, J.Q. Xu, and E. Ward Cancer Statistics, 2010 CA Cancer J. Clin. 60 5 2010 277 300
2. F. Bray, J. Lortet-Tieulent, J. Ferlay, D. Forman, and A. Auvinen Prostate cancer incidence and mortality trends in 37 European countries: an overview Eur. J. Cancer 46 17 2010 3040 3052
3. N. Mottet, J. Bellmunt, M. Bolla, S. Joniau, M. Mason, V. Matveev, H.P. Schmid, K.T. Van der, T. Wiegel, F. Zattoni, and A. Heidenreich EAU Guidelines on Prostate Cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur. Urol. 59 2011 572 583
4. B. Tombal, and R. Berges Optimal testosterone control and Eligard (R) Eur. Urol. Suppl. 6 12 2007 754 760
5. F. Labrie, A. Belanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J. Gomez, and B. Candas Gonadotropin-releasing hormone agonists in the treatment of prostate cancer Endocr. Rev. 26 3 2005 361 379
6. B. Tombal The importance of testosterone control in prostate cancer Eur. Urol. Suppl. 6 15 2007 834 839
7. T. Trimaille, R. Gurny, and M. Moller Poly(hexyl-substituted lactides): novel injectable hydrophobic drug delivery systems J. Biomed. Mater. Res. A 80A 1 2007 55 65
8. G. Williams, S. Lindsay, and W.G. Bowsher Randomised crossover trial to assess the tolerability of LHRH analogue administration Prostate Cancer Prostatic Dis. 6 2 2003 187 189
9. C. Wischke, and S.P. Schwendeman Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles Int. J. Pharm. 364 2 2008 298 327
10. H. Kranz, and R. Bodmeier Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles Eur. J. Pharm. Sci. 34 2-3 2008 164 172
11. L.R. Asmus, R. Gurny, and M. Möller Solutions as solutions - synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulate sustained-release parenterals Eur. J. Pharm. Biopharm. 79 3 2011 584 591
12. L.R. Asmus, B. Kaufmann, L. Melander, T. Weiss, G. Schwach, R. Gurny, and M. Moller Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer Eur. J. Pharm. Biopharm. 81 3 2012 591 599
13. C. Witschi, and E. Doelker Peptide degradation during preparation and in vitro release testing of poly(l-lactic acid) and poly(dl-lactic-co-glycolic acid) microparticles Int. J. Pharm. 171 1 1998 1 18
14. A. Rothen-Weinhold, N. Oudry, K. Schwach-Abdellaoui, S. Frutiger-Hughes, G.J. Hughes, D. Jeannerat, U. Burger, K. Besseghir, and R. Gurny Formation of peptide impurities in polyester matrices during implant manufacturing Eur. J. Pharm. Biopharm. 49 3 2000 253 257
15. M.L. Houchin, S.A. Neuenswander, and E.M. Topp Effect of excipients on PLGA film degradation and the stability of an incorporated peptide J. Control. Release 117 3 2007 413 420
16. M.A. Ibrahim, A. Ismail, M.I. Fetouh, and A. Gopferich Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres J. Control. Release 106 3 2005 241 252
17. G. Novara, A. Galfano, S. Secco, V. Ficarra, and W. Artibani Impact of surgical and medical castration on serum testosterone level in prostate cancer patients Urol. Int. 82 3 2009 249 255
18. M. Filicori, G.E. Cognigni, R. Arnone, P. Pocognoli, C. Tabarelli, W. Ciampaglia, S. Taraborelli, and P. Casadio Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women Fertil. Steril. 69 3 1998 443 449
19. W.H. De Jong, J.E. Bergsma, J.E. Robinson, and R.R.M. Bos Tissue response to partially in vitro predegraded poly-l-lactide implants Biomaterials 26 14 2005 1781 1791
20. L. Requena, C. Requena, L. Christensen, U.S. Zimmermann, H. Kutzner, and L. Cerroni Adverse reactions to injectable soft tissue fillers J. Am. Acad. Dermatol. 64 1 2011 1 34
21. J.L. Sun, G.Q. Jiang, T.T. Qiu, Y.J. Wang, K. Zhang, and F.X. Ding Injectable chitosan-based hydrogel for implantable drug delivery: body response and induced variations of structure and composition J. Biomed. Mater. Res. A 95A 4 2010 1019 1027
22. K. Mader, B. Gallez, K.J. Liu, and H.M. Swartz Non-invasive in vivo characterization of release processes in biodegradable polymers by low-frequency electron paramagnetic resonance spectroscopy Biomaterials 17 4 1996 457 461
23. A. Lucke, J. Kiermaier, and A. Gopferich Peptide acylation by poly(alpha-hydroxy esters) Pharm. Res. 19 2 2002 175 181
24. D.H. Na, J.E. Lee, S.W. Jang, and K.C. Lee Formation of acylated growth hormone-releasing peptide-6 by poly(lactide-co-glycolide) and its biological activity AAPS PharmSciTech 8 2 2007
25. M.A. Qasim, and A. Salahuddin Changes in conformation and immunological activity of ovalbumin during its modification with different acid anhydrides Biochim. Biophys. Acta 536 1 1978 50 63
26. A. Rawat, and D.J. Burgess Effect of physical ageing on the performance of dexamethasone loaded PLGA microspheres Int. J. Pharm. 415 1-2 2011 164 168
27. N.A. Weir, F.J. Buchanan, J.F. Orr, D.F. Farrar, and A. Boyd Processing, annealing and sterilisation of poly-l-lactide Biomaterials 25 18 2004 3939 3949
28. O. Bouchot, J.Y. Soret, D. Jacqmin, N. Lahlou, M. Roger, and J. Blumberg Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study Horm. Res. 50 2 1998 89 93
29. J. Emami In vitro-in vivo correlation: from theory to applications J. Pharm. Pharm. Sci. 9 2 2006 169 189